Recent News

• 03.30.2026 - Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
• 03.23.2026 - Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
• 03.16.2026 - Phio Pharmaceuticals Announces “A Groundbreaking Approach to Treating Skin Cancer” in a Fireside Chat with Force Family Office
• 03.10.2026 - Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
• 03.05.2026 - Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
• 03.05.2026 - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
• 02.19.2026 - Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
• 02.10.2026 - Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Recent Filings

• 03.05.2026 - 8-K Current report
• 03.05.2026 - EX-99.1 EX-99.1
• 03.05.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.18.2026 - 8-K Current report
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2026 - 8-K Current report
• 02.10.2026 - EX-99.1 EX-99.1
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities